Examkin

Soru

Zorluk: ZorMedical History Evaluation

An internal medicine physician is called to the emergency department to evaluate a 61-year-old woman complaining of severe nausea, generalized weakness, and visual changes. She states that over the past 48 hours, she has been seeing "yellowish halos" around lights. Her medical history includes heart failure with reduced ejection fraction, persistent atrial fibrillation, and osteoarthritis. Her chronic daily medications include carvedilol, sacubitril-valsartan, digoxin, and rivaroxaban. Five days ago, she visited an urgent care clinic for purulent nasal discharge and facial pressure, for which she was prescribed a 7-day course of clarithromycin. Since then, she has also been taking over-the-counter naproxen twice daily for sinus headaches and drinking a homemade ginger-root tea to soothe her throat.

Vital signs show a heart rate of 46/min and irregular, blood pressure of 102/65 mmHg, and oxygen saturation of 97% on room air. Physical examination reveals clear lungs bilaterally and no lower extremity edema. Laboratory studies show a serum creatinine of 1.1 mg/dL (baseline 1.0 mg/dL) and a serum potassium of 4.2 mEq/L.

Based on the comprehensive medical history and clinical findings, which of the following historical elements is the primary precipitant of this patient's current syndrome?

  1. Initiation of clarithromycin therapyCevap
  2. B
    Increased frequency of naproxen use
  3. C
    Consumption of ginger-root tea
  4. D
    Long-term sacubitril-valsartan therapy
  5. E
    Progression of underlying heart failure

Cevap

Initiation of clarithromycin therapy
The correct answer identifies the recent addition of a macrolide antibiotic as the catalyst for the patient's symptoms. The triad of gastrointestinal distress, bradycardia, and xanthopsia (yellow-tinted vision/halos) in a patient taking digoxin is pathognomonic for digoxin toxicity. Digoxin is primarily excreted unchanged by the kidneys and is heavily reliant on P-glycoprotein (P-gp) for both intestinal efflux and renal tubular secretion. Clarithromycin is a potent inhibitor of both cytochrome P450 3A4 and P-gp. The inhibition of P-gp significantly increases digoxin bioavailability and decreases its clearance, leading to rapid systemic accumulation and toxicity. Recognizing this requires careful evaluation of the patient's recent medical and pharmacological history.

Adım Adım Çözüm

1
Analyze the clinical presentation.
The patient exhibits severe nausea, profound bradycardia (HR 46/min), and visual changes described as "yellowish halos" (xanthopsia).
Recognizing this classic triad establishes a presumptive diagnosis of acute-on-chronic digoxin toxicity.
2
Evaluate the medical history for precipitants.
Recent changes include starting clarithromycin, increasing naproxen use, and consuming ginger tea.
Identifying all new historical inputs is essential to pinpoint the trigger for the adverse drug event.
3
Assess the patient's laboratory values in the context of the history.
Serum creatinine is 1.1 mg/dL, which is very close to her baseline of 1.0 mg/dL. Potassium is normal at 4.2 mEq/L.
This rules out significant acute kidney injury (which could have been caused by naproxen) and hypokalemia as the primary drivers of the digoxin toxicity.
4
Identify the pharmacokinetic mechanism causing the toxicity.
Clarithromycin is a potent inhibitor of P-glycoprotein (P-gp).
Since digoxin is a substrate for P-gp, its inhibition drastically reduces digoxin's renal and intestinal efflux, causing serum levels to rise to toxic ranges.

Anahtar Kavram

Pharmacokinetic evaluation of drug interactions involving P-glycoprotein inhibitors
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Medical History Evaluation

Bu konudan daha fazla soru